5 Key Takeaways

• 1

  Bristol Myers Squibb has terminated its partnership with Cellares for the manufacturing of CAR T-cell therapy Breyanzi.

• 2

  Cellares disputes Bristol Myers' assessment that its Cell Shuttle platform cannot meet Breyanzi's manufacturing requirements.

• 3

  The end of the partnership will lead to approximately 100 job cuts at Cellares' facility in South San Francisco.

• 4

  A first-in-human gene therapy study for sickle cell disease showed faster collection and modification of blood stem cells.

• 5

  Researchers at St. Jude found that deleting the Regnase-1 gene from CAR T cells improved tumor control in osteosarcoma models.